Cancer Research Technology Limited

Other

Heartfelt Technologies Limited

Cambridge Temperature Concepts Limited

Gareth Paul Williams

Ronald Alfred Laskey

Nicholas Coleman

Jonathan Michael Hayes

Oriane Elisabeth Chausiaux

Shamus Louis Godfrey Husheer

Michal Nieznañski

A method of identifying fluid retention in a body part of the patient by directly or indirectly measuring a first parameter relating to a size of a body part of the patient to obtain an actual measurement of the body part, obtaining an estimated measurement of said first parameter relating to the size of the body part of the patient by measuring alternative predefined parameters of the patient, wherein said estimated measurement is calculated based on a mathematical relationship between said alternative parameters and the size of the body part; and correlating the actual and estimated measurements of the body part of the patient to assess any fluid retention in the body part.

System and method for identifying fluid retention in a body part

A workbench comprising a first support, a second support and a first work surface, in which said first support comprises a leg structure with an upper end, in which said first work surface comprises a first end, in which said upper end and said first end comprise a connection means to releasably connect them together, and in which said connection means comprises a first pair of parallel elongate troughs provided on either said upper end or said first end, and a first pair of parallel elongate flanges provided on the other of said upper end or said first end, which first pair of flanges is shaped and configured to be releasably engagable in said first pair of troughs.

Workbench

An electronic device comprising: a processor having a motion activation mode and an operating mode; an orientation sensor operable to detect the orientation of the device, and a clock configured to, when the processor is in the motion activation mode, periodically power-up the processor; wherein the processor is configured to, when powered-up in its motion activation mode, obtain a measurement of the orientation of the device from the orientation sensor; store the obtained measurement; and process the obtained measurement in dependence on one or more stored measurements of the orientation of the device so as to determine whether the obtained measurement and the one or more stored measurements are indicative of a predetermined sequence of orientations of the device; the processor being configured to transition from its motion activation mode to its operating mode in response to determining that the obtained measurement and the one or more stored measurements are indicative of the predetermined sequence of orientations of the device.

Activating an electronic device

Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, esophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and pre-cancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma.

Detection of dysplastic or neoplastic cells using anti-MCM3 antibodies

Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, oesophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and pre-cancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma.

Detection of dysplastic or neoplastic cells using anti-MCM6 antibodies

Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, esophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and pre-cancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of hematological malignancies and evidence of metastatic sarcoma and carcinoma.

Detection of dysplastic or neoplastic cells using anti-MCM2 antibodies

Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, oesophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and precancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma.

Growing community of inventors

Cambridge, United Kingdom

Gareth Paul Williams